bpx-501
Cell therapyexperimental
Clinical trial activity
11 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2013 (NCT01744223)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Anemia, Aplastic · Phase 1/Phase 2
- Anemia, Diamond-Blackfan · Phase 1/Phase 2
- Anemia, Sickle Cell · Phase 1/Phase 2
- Congenital Bone Marrow Failure Syndromes · Phase 1
- Fanconi Anemia · Phase 1/Phase 2
- Hematologic Neoplasms · Phase 1
- Hemoglobinopathies · Phase 1/Phase 2
- Leukemia · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Leukemia, Myelomonocytic, Chronic · Phase 1
- Lymphohistiocytosis, Hemophagocytic · Phase 1
- Lymphoma · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Metabolic Diseases · Phase 1
- Multiple Myeloma · Phase 1
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Myeloproliferative Disorders · Phase 1
- Neoplasms · Phase 1
- Osteopetrosis · Phase 1/Phase 2
- Pediatrics · Phase 1/Phase 2
- Plasmacytoma · Phase 1
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
- Primary Immunodeficiency Diseases · Phase 1/Phase 2
- Thalassemia · Phase 1/Phase 2
- Thrombocytopenia · Phase 1/Phase 2
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bpx-501
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03807063 | Phase 1 | Jul 1, 2019 | Bellicum Pharmaceuticals, National Cancer Institute (NCI), University of Washington |
| NCT03459170 | Phase 1 | Feb 1, 2018 | Bellicum Pharmaceuticals, IRCCS Ospedale, Rome, Italy |
| NCT02786485 | Phase 1 | May 1, 2017 | Bellicum Pharmaceuticals, State University of New York, Buffalo |
| NCT02487459 | Phase 1 | May 1, 2017 | Bellicum Pharmaceuticals, University of Texas at Houston |
| NCT03733249 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2017 | Bellicum Pharmaceuticals, Sponsor GmbH |
| NCT02477878 | Phase 1 | Jul 1, 2016 | Bellicum Pharmaceuticals, The University of Texas, Dallas |
| NCT02231710 | Phase 1 | Feb 1, 2015 | Bellicum Pharmaceuticals, University of Washington |
| NCT02065869 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2014 | Bellicum Pharmaceuticals |
| NCT03301168 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2014 | Bellicum Pharmaceuticals, Children's Hospital Los Angeles |
| NCT01744223 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2013 | Bellicum Pharmaceuticals, Case Western Reserve University |
| NCT03639844 | N/A | — | Bellicum Pharmaceuticals |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bellicum Pharmaceuticals | For profit | 11 | 10 | 3 | 2013 |
| University of Washington | Academic/Hospital | 2 | 1 | 1 | 2015 |
| Case Western Reserve University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Children's Hospital Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2014 |
| IRCCS Ospedale, Rome, Italy | Academic/Hospital | 1 | 0 | 1 | 2018 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2019 |
| Sponsor GmbH | Academic/Hospital | 1 | 0 | 1 | 2017 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 0 | 1 | 2017 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2017 |
10 organizations
Page 1 / 1